Trial Profile
An Open-label, Multicenter, Controlled Pharmaco-dynamic Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease in Comparison to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Thiethylperazine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics; Proof of concept
- Acronyms drainAD
- Sponsors Immungenetics
- 29 Mar 2022 Status changed from active, no longer recruiting to completed.
- 24 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Dec 2021.
- 24 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Oct 2021.